Jean Luc Harousseau

TL;DR: Young patients were more frequently male, had more favorable features such as low International Staging System and Durie-Salmon stage as well as less frequently adverse prognostic factors including high C-reactive protein (CRP), low hemoglobin, increased serum creatinine, and poor performance status, and seem to account for the significantly longer survival of young patients with multiple myeloma.

TL;DR: UCBT is a viable treatment for adults with advanced lymphoid malignancies and Chemosensitive disease, use of low-dose TBI, and higher cell dose were factors associated with significantly better outcome.

TL;DR: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher incidence of grade 3 neurotoxicity.

TL;DR: Results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency, and is more effective than dexamethasone in overcoming the detrimental effect of renal impairment.

TL;DR: TAMLs with t(8;21), inv(16), or t( 8;16) are usually characterized by a short latent period, previous treatment often combining a drug that directly reacts with DNA and an ATTop, and absence of preleukemic phase.